BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 16011671)

  • 1. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.
    Johnson DA; Stacy T; Ryan M; Wootton T; Willis J; Hornbuckle K; Brooks W; Doviak M
    Aliment Pharmacol Ther; 2005 Jul; 22(2):129-34. PubMed ID: 16011671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial: intragastric acid control in patients who have Barrett's oesophagus--comparison of once- and twice-daily regimens of esomeprazole and lansoprazole.
    Spechler SJ; Barker PN; Silberg DG
    Aliment Pharmacol Ther; 2009 Jul; 30(2):138-45. PubMed ID: 19438416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
    Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
    Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P; Katz PO; Chen Y; Sostek M
    Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acid control with esomeprazole and lansoprazole: a comparative dose-response study.
    Wilder-Smith C; Lind T; Lundin C; Nauclér E; Nilsson-Pieschl C; Röhss K
    Scand J Gastroenterol; 2007 Feb; 42(2):157-64. PubMed ID: 17327934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole.
    Morgan D; Pandolfino J; Katz PO; Goldstein JL; Barker PN; Illueca M
    Aliment Pharmacol Ther; 2010 Jul; 32(2):200-8. PubMed ID: 20456300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study.
    Katz PO; Castell DO; Chen Y; Andersson T; Sostek MB
    Aliment Pharmacol Ther; 2004 Aug; 20(4):399-406. PubMed ID: 15298633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
    Frazzoni M; Manno M; De Micheli E; Savarino V
    Dig Liver Dis; 2006 Feb; 38(2):85-90. PubMed ID: 16289976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study.
    Miehlke S; Madisch A; Kirsch C; Lindner F; Kuhlisch E; Laass M; Knoth H; Morgner A; Labenz J
    Aliment Pharmacol Ther; 2005 Apr; 21(8):963-7. PubMed ID: 15813831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.
    Goldstein JL; Miner PB; Schlesinger PK; Liu S; Silberg DG
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1189-96. PubMed ID: 16611280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: is stringent control of gastric pH useful and practical in GERD?
    Kahrilas PJ
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():89-94; discussion 95-6. PubMed ID: 15456470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study.
    Tsai HH; Chapman R; Shepherd A; McKeith D; Anderson M; Vearer D; Duggan S; Rosen JP;
    Aliment Pharmacol Ther; 2004 Sep; 20(6):657-65. PubMed ID: 15352914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
    Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
    Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K; Lind T; Wilder-Smith C
    Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
    Castell D; Bagin R; Goldlust B; Major J; Hepburn B
    Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study.
    Wilder-Smith CH; Röhss K; Bondarov P; Hallerbäck B; Svedberg LE; Ahlbom H
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1099-104. PubMed ID: 15569112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
    Howden CW; Ballard ED; Koch FK; Gautille TC; Bagin RG
    J Clin Gastroenterol; 2009 Apr; 43(4):323-6. PubMed ID: 18758373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.
    Junghard O; Hassan-Alin M; Hasselgren G
    Eur J Clin Pharmacol; 2002 Oct; 58(7):453-8. PubMed ID: 12389067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.
    Devault KR; Johanson JF; Johnson DA; Liu S; Sostek MB
    Clin Gastroenterol Hepatol; 2006 Jul; 4(7):852-9. PubMed ID: 16682260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial.
    Li ZS; Zhan XB; Xu GM; Cheng NN; Liao Z
    J Gastroenterol Hepatol; 2007 Jun; 22(6):815-20. PubMed ID: 17565634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.